KLK3 and Familial prostate cancer: Therefore, using individual patient data from the available RCTs from the Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) Consortium database, we evaluated whether adding docetaxel to testosterone suppression plus curative local treatment (radiotherapy or RP) can reduce prostate cancer–specific mortality (PCSM) and all-cause mortality (ACM) in patients with localized or locally advanced nonmetastatic prostate cancer who have both a PSA level of less than 4 ng/mL and a biopsy Gleason score of 8 to 10 and are in otherwise good health with performance status defined as 0.